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ABSTRACT Zn-a2-glycoprotein (ZAG) is a 41-kDa solu-
ble protein that is present in most bodily f luids. In addition,
ZAG accumulates in f luids from breast cysts and in 40% of
breast carcinomas, which suggests that ZAG plays a role in the
development of breast diseases. However, the function of ZAG
under physiological and cancerous conditions remains un-
known. Because ZAG shares 30–40% sequence identity with
the heavy chains of class I major histocompatibility complex
(MHC) proteins, we compared the biochemical properties of
ZAG with those of classical class I MHC molecules. We
purified human ZAG from breast cyst f luid and serum and
produced a panel of anti-ZAGmonoclonal antibodies. Binding
assays and acid elution experiments revealed that, in contrast
to class I MHC proteins, ZAG does not bind peptides or the
class I light chain, b2-microglobulin (b2m). Nevertheless, CD
studies indicated that ZAG is thermally stable in the absence
of bound peptide or associated b2m, as opposed to class I
MHC molecules, which require the presence of both b2m and
peptides for stability. These data indicate that the function of
ZAG has diverged from the peptide presentation and T-cell
interaction functions of class I molecules. To gain insight into
the function of ZAG and to compare the three-dimensional
structures of ZAG and class I MHC molecules, we produced
ZAG crystals that diffract beyond 2.7 Å and have initiated an
x-ray structure determination.
Zn-a2-glycoprotein (ZAG) is a soluble protein that was orig-
inally isolated from human plasma (1). Its name derives from
its tendency to precipitate with zinc salts, its electrophoretic
mobility in the region of the a2 globulins, and its 18%
carbohydrate content. The function of ZAG is unknown, but
several studies have shown that this protein is present in other
bodily f luids, including sweat, saliva, cerebrospinal f luid, sem-
inal plasma, milk, ammiotic f luid, and urine (2). In addition,
ZAG is found at high concentrations in the fluid from breast
cysts and in 40% of breast carcinomas (3–6). These findings,
together with the fact that ZAG is induced by glucocorticoids
and androgens in breast cancer cell lines (7), suggest that this
protein may participate in the development of mammary
diseases, including breast cancer.
Amino acid sequence analysis revealed that ZAG is surpris-
ingly similar to class I major histocompatibility complex
(MHC) proteins (8). Class IMHCmolecules are heterodimers,
consisting of a membrane-bound heavy chain noncovalently
associated with b2-microglobulin (b2m), a soluble protein that
serves as the light chain. Class I molecules bind peptides
derived from intracellular proteins and present them to cyto-
toxic T cells during immune surveillance (9). Crystal structures
reveal that they fold into a shape ideally suited for peptide
binding. Two long a-helices form the sides of a groove within
the first two domains (a1 and a2) of the heavy chain, and a
b-pleated sheet forms the bottom. The b2m light chain and the
other domain of the heavy chain (a3) lie underneath the a1 and
a2 domains, with b2m interacting simultaneously with the side
of the a3 domain and the bottom of the a1-a2 domain platform
(reviewed in refs. 10 and 11). ZAG is composed of three
domains that share 30–40% amino acid sequence identity with
the three extracellular domains of class I heavy chains. This
level of sequence identity is compatible with structural simi-
larity, as shown by Chothia and Lesk (12).
Analysis of ZAG cDNA and genomic clones provided
further data about the relationship between ZAG and class I
MHCmolecules (13). Similarities in exon organization, intron-
exon junctions, and nucleotide sequence indicate that the
coding regions of the ZAG gene are homologous to the first
four exons of MHC genes, which encode the signal peptide and
the three extracellular domains of the heavy chain. However,
the ZAG gene does not encode transmembrane or cytoplasmic
regions and lacks the regulatory and interferon consensus
sequences that are conserved in typical MHC genes (13). In
addition, the ZAG gene differs from class I genes in its lack of
polymorphism and in its location outside of theMHC (14). The
recent identification of cDNAs coding for ZAG in mice and
rats (15, 16) shows that the divergence between ZAG and
MHCmolecules began at least 80 million years ago, before the
evolutionary radiation of the placental mammals (17).
This work addresses how this divergence has affected the
biochemical and structural characteristics of ZAG. We puri-
fied human ZAG from fluid obtained from breast cysts and
from serum, produced anti-ZAG mAbs, and compared its
properties with those of class I MHC molecules. In addition,
as a first step in a three-dimensional structure determination,
we produced crystals of ZAG that are suitable for an x-ray
diffraction analysis.
MATERIALS AND METHODS
Materials. Fluid from breast cysts obtained from patients
with breast gross cystic disease was kindly provided by F.
Vizoso from Hospital de Jove (Gijo´n, Spain). Human serum
was the gift of J. Goin, from Biocell Laboratories. Samples
were stored at 2208C. Before use, fats and debris were
removed by centrifugation at 10,0003 g and filtration through
0.2 mm filters. Human b2m and anti-b2m polyclonal antiserum
were from Sigma. Chromatographic matrices and equipment
were from Pharmacia. Antibody isotyping was performed with
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a kit from GIBCOyBRL. 125I-protein A was from Amersham.
Native PAGE was performed using a PhastSystem (Pharma-
cia).
Purification of ZAG from Breast Cyst Fluid. Seventy-five
milliliters of cyst f luid was loaded on a phenyl Sepharose
column equilibrated with 50 mM sodium phosphate (pH 7),
0.75 M (NH4)2SO4. The column was washed with 0.25 M
(NH4)2SO4 in sodium phosphate, and ZAG was eluted with 50
mM sodium phosphate (pH 7). Fractions containing ZAG
were applied on a nickel-chelating Sepharose column equili-
brated with 50 mM sodium phosphate (pH 7.5), 0.5 M NaCl.
ZAG was recovered in the flowthrough, while contaminant
proteins were retained on the chelating column. ZAG was
further purified by chromatography on a Superdex 200 HiLoad
FPLC column equilibrated in 20 mM Hepes (pH 7), 150 mM
NaCl. Purified ZAG was desalted and concentrated using a
Centricon-10 (molecular weight cutoff of 10,000) ultrafiltra-
tion device (Amicon) and stored in 20 mM Hepes (pH 7),
0.02% NaN3 at 48C.
Antibodies.Rabbit anti-ZAG polyclonal antiserum was pro-
duced as described (4). Female BALByc mice (aged 5 weeks)
were primed and twice boosted at 2-week intervals by intra-
peritoneal injection of 100 mg of purified ZAG in adjuvant.
Serum was screened a week after each injection by ELISA as
described (18). Three days preceding the fusion, one mouse
was boosted with 100 mg of purified ZAG. Splenocytes from
the boosted mouse were fused with HL-1 murine myeloma
cells, and media from the hybridoma cultures were tested for
antibodies against ZAG by ELISA. After subcloning positive
clones at clonal density, ascites tumors were produced in
pristane-primed BALByc mice. Eight anti-ZAG mAbs pro-
duced by this fusion were subsequently characterized (Table
1). All antibodies are murine IgG1-k. Conditions for elution of
ZAG were determined by ELISA as described (19).
Purification of ZAG from Human Serum. Seventy-five
milligrams of the purified mAb 3C5 were coupled to a CNBr-
activated Sepharose column according to the manufacturer’s
instructions. Two-hundred-fifty-milliliter aliquots of serum
were loaded on the 3C5 immunoaffinity column equilibrated
with 20 mM of sodium phosphate (pH 7.5), 0.5 M NaCl. After
washing with the same buffer, ZAG was eluted with 20 mM
sodium acetate (pH 4.5), 0.5 M NaCl into tubes containing
Hepes (pH 7). Fractions containing ZAG were desalted and
loaded on a Q Sepharose column equilibrated with 20 mM of
piperazine (pH 5). For biochemical experiments, ZAG was
eluted using 0.1 M NaCl in the piperazine buffer and stored as
before. For crystalization, ZAG was eluted using a gradient
from 0 to 50 mM NaCl in the piperazine buffer. Under these
conditions, ZAG eluted in two peaks. The peak that eluted in
higher salt was loaded on a Source phenyl column equilibrated
with 50 mM sodium phosphate (pH 6), 0.75 M (NH4)2SO4 and
eluted with a gradient from 0.75 M to 0 M (NH4)2SO4 in the
same buffer. ZAG was further separated into two peaks that
eluted with 0.56 M and 0.41 M (NH4)2SO4, respectively.
b2m Binding Assays. For chromatographic experiments, 4
mg of ZAG were mixed with 1 to 30 mg of b2m in 25 ml of
Tris-buffered saline. After 6 h, the sample was injected on a
SMART system Superdex 75 Precision column equilibrated in
the same buffer. Absorbance was measured at 280 nm, and
fractions were analyzed by SDSyPAGE. For immunoprecipi-
tation assays, 1-ml aliquots of serum were incubated with 25 ml
of protein A Sepharose for 30 min. After pelleting, superna-
tants were incubated for 1 h with 10 mg of polyclonal antiserum
against ZAG or b2m, followed by a 30-min incubation with
protein A Sepharose. The resins were pelleted and washed
with Tris-buffered saline containing 0.1%BSA, 0.1% SDS, 1%
Nonidet P-40, and 1% sodium deoxycholate. The immunopre-
cipitated proteins were separated by SDSyPAGE and blotted
onto nitrocellulose filters, which were incubated with anti-
serum against either ZAG or b2m and developed with 125I-
protein A following published protocols (4).
Acid Elutions of ZAG or a Class I MHC Heterodimer
(H-2Kd). Purified ZAG from serum or H-2Kd (a soluble
version of the Kd heavy chain complexed with human b2m (20);
proteins were analyzed for the presence of bound peptides
using established methods (21, 22). Aliquots of 1 mg of protein
were diluted into 1 ml of 10% acetic acid, boiled for 5 min, and
filtered in a centricon 3 (molecular weight cutoff of 3,000)
ultrafiltration device. The filtrates were analyzed on a SMART
system mRPC C2yC18 SC column using a 6 ml gradient from
0.06% trif luoroacetic acid in water to 0.05% trif luoroacetic
acid in 80% acetonitrile. Absorbance was monitored at 214
nm. The fractions containing peaks were microsequenced
using an ABI 477A protein sequencer with a 120A phenyl-
thiohydantoin analyzer as described (4). To detect N-
terminally blocked peptides, peaks from a similar experiment
were analyzed by matrix-assisted, laser desorption, time-of-
f light mass spectrometry using a PerSeptive Biosystems (Fra-
mingham, MA) ELITE mass spectrometer.
Thermal Stability Analyses. An Aviv 62A DS spectropola-
rimeter equipped with a thermoelectric cell holder and a 1-mm
path-length cell was used for CD studies. The heat-induced
unfolding of ZAG [1 mgyml in 5 mM sodium phosphate (pH
7)] was monitored by recording the CD signal at 223 nm while
the sample temperature was raised from 258 to 808C at a rate
of 208C per hour. The transition midpoint (Tm) was calculated
by estimating the half-point of the ellipticity change between
the pure native and the pure denatured states. Thermal
stability measurements were repeated after denaturation in 6
M guanidine hydrochloride, dialysis against denaturant, and
refolding by dialysis against 5 mM sodium phosphate (pH 7).
Crystalization of ZAG. Initial crystalization conditions were
obtained from factorial trial screens (23). The best crystals
were obtained using serum ZAG eluted with 0.56 M
(NH4)2SO4 from the Source phenyl column. Single crystals
were grown by vapor diffusion from protein solutions (15
mgyml) in 20 mM Hepes (pH 7.0), 0.02% NaN3, in 3-ml
droplets with 30% (wtyvol) polyethylene glycol 2000 mono-
methyl ether (Fluka), 0.2 M ammonium acetate, 0.1 M sodium
acetate (pH 5). After crystals were formed, the concentration
of polyethylene glycol was raised to 35% for cryopreservation.
Single crystals were mounted in a thin film of cryopreservation
buffer, supported by a rayon loop (24), and quickly cooled by
plunging into liquid nitrogen.
RESULTS
Purification of ZAG. High levels of ZAG are found in the
fluid from breast cysts obtained from patients with breast gross
cystic disease (4). We developed a purification protocol for
isolation of ZAG from breast cyst f luid, which yielded about
20 mg of ZAG per 75 ml of fluid. The purification procedure
included three successive chromatographic steps: hydrophobic
interaction, metal chelating, and size exclusion chromatogra-
Table 1. mAbs against ZAG
Clone
name
Western
blot
Immuno-
precipitation
pH required
for elution
of ZAG
1B5 1 1 4.0
1D4 11 11 4.0
1E2 11 11 3.0
1H4 1 11 3.0
3C5 11 1 4.5
3F4 1y2 11 3.5
4E3 2 1 3.5
6G2 11 11 3.5
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phy, and resulted in protein that was apparently homogeneous,
as judged by SDSyPAGE (Fig. 1). However, subsequent
analysis by native PAGE (Fig. 1) revealed heterogeneity in the
protein preparation, and multiple crystalization trials failed to
produce protein crystals of x-ray diffraction quality. We there-
fore decided to purify ZAG from another source.
To facilitate purification of ZAG from human serum, mAbs
were produced against ZAG purified from breast cyst f luid.
The anti-ZAG mAb 3C5 was immobilized on a solid support,
and ZAG was purified by immunoaffinity and ion exchange
chromatography from serum at yields up to 15 mgyliter.
SDSyPAGE (Fig. 1) and mass spectrometry showed that both
serum and cyst f luid ZAG have the samemolecular mass (396
1 kDa by mass spectrometry; data not shown). However, native
PAGE analysis revealed that ZAG isolated from serum was
more homogeneous than ZAG isolated from cyst f luid (Fig. 1).
Therefore, serum ZAG was used for the subsequent experi-
ments.
b2m Binding Assays. The heavy chains of classical class I
MHC proteins are tightly associated with b2m (25). However,
purified preparations of ZAG show a single band with an
apparent molecular mass of 41 kDa when analyzed by SDSy
PAGE, with no sign of a 12-kDa light chain corresponding to
b2m (Fig. 1). To ascertain if ZAG binds b2m, different ratios
of both proteins were incubated and analyzed by size exclusion
chromatography. Regardless of the ZAGyb2m ratio loaded on
the column, only peaks containing either ZAG or b2m, but not
both proteins, were obtained (Fig. 2A). In addition, b2m
binding was not observed using a surface plasmon resonance-
based assay in which b2m was passed over a ZAG-coupled
biosensor chip (data not shown).
The result that purified ZAG does not associate with b2m
was confirmed for ZAG in serum using immunoprecipitation
assays. Western blot analysis showed that an anti-ZAG anti-
serum precipitated ZAG from serum, but did not coprecipi-
tate b2m. Conversely, an anti-b2m antiserum precipitated b2m
from serum, but did not coprecipitate ZAG (Fig. 2B).
Peptide Elution Assays. Peptides associated with class I
MHC molecules have typically been analyzed by N-terminal
sequencing of eluates recovered after ultrafiltration of acid
dissociated heterodimers (21, 22). To determine whether ZAG
contains bound peptide(s), we compared acid eluates of
purified ZAG and the murine class I MHC molecule H-2Kd.
Acid eluates were analyzed by reverse phase chromatography
(Fig. 3) and N-terminal sequencing. This procedure resulted in
identification of multiple peptides in the Kd acid eluate whose
sequences corresponded to the previously characterized motif
for peptides bound to this class I allele (26). By contrast, most
of the peaks in the chromatographic profile of the ZAG acid
eluate also were found in eluates extracted from samples
without protein, and peptides were not detected in any of the
peaks by N-terminal sequencing or by mass spectrometry. Pool
sequencing of unpurified acid eluates produced comparable
results: peptides were detected in the Kd eluate, but not in the
ZAG eluate (data not shown).
Thermal Stability of ZAG. Class I MHC heavy chains show
decreased stability in the absence of peptide (20, 27, 28) or
b2m (29), whereas ZAG exists as an isolated class I MHC-like
heavy chain without bound peptides. To ascertain if ZAG is
less stable than class I MHC molecules because of the absence
of bound peptide and light chain, we monitored the heat-
induced unfolding of ZAG by recording the CD signal at 223
nmwhile increasing the sample temperature from 258C to 808C
(Fig. 4). The resulting melting curve shows a Tm of 658C, which
is comparable to previously obtained Tms for peptide-filled
class I MHC molecules [H-2Kd: 578C; (20); HLA-A2: 668C;
(30)]. The Tm obtained from the ZAG melting curve is
substantially higher than the Tm of an empty class I MHC
molecule (H-2Kd complexed with human or murine b2m:
43–458C; refs. 20 and 31).
Crystalization. ZAG forms crystals of approximate dimen-
sions 0.4 mm 3 0.2 mm 3 0.1 mm in space group P21212. The
unit cell dimensions are a 5 106 Å, b 5 132 Å, and c 5 119
Å. The asymmetric unit of the crystal is estimated to contain
two to six molecules based on average volume to mass ratios
FIG. 1. PAGE analysis of ZAG. Aliquots of ZAG purified from
breast cyst f luid or serum were analyzed by SDSy10–15% PAGE and
nativey8–20% PAGE.
FIG. 2. Chromatographic and immunoprecipitation analyses con-
firm that ZAG does not bind b2m. (A) b2m (Top), ZAG (Middle), and
a mixture of ZAG incubated with b2m (Bottom) were analyzed by size
exclusion chromatography. (Inset) SDSy13% PAGE analysis of the
peaks in the bottom panel. (B) Aliquots of ZAG, serum, and b2m were
immunoprecipitated with either anti-ZAG or anti-b2m antibodies.
Precipitated proteins were analyzed by Western blot using antisera
against either ZAG or b2m.
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(Vm) of protein crystals (32), representing solvents contents
between 76% (assuming two molecules per asymmetic unit) to
27% (assuming six molecules per asymmetric unit). Crystals
were equilibrated in a cryopreservative and subjected to x-ray
analysis at 21658C (33). Cryopreserved crystals diffract to 3.2
Å resolution using CuKa radiation from a Rigaku R200
rotating anode x-ray generator. The use of a synchrotron x-ray
source improves the resolution limit. Using the A1 beam line
at the Cornell High Energy Synchrotron Source (CHESS),
data were collected to 2.7 Å resolution from cryopreserved
crystals.We are in the process of solving the three-dimensional
structure of ZAG using molecular and isomorphous replace-
ment methods.
DISCUSSION
ZAG is a class I MHC homolog produced by secretory
epithelial cells that is present in most bodily f luids (2). Because
of increased concentrations of ZAG in mammary carcinomas
and in cyst f luids from women with gross cystic disease of the
breast, it has been suggested that ZAG participates in the
development of breast diseases (4). Indeed, ZAG levels are
higher in well differentiated breast carcinomas, indicating that
ZAG is a biochemical marker of differentiation in breast
cancer (5). In this study, we have purified human ZAG from
both breast cyst f luids and serum, and compared a series of
biochemical characteristics to those of class I MHC molecules.
Milligram amounts of ZAG were purified from cyst f luid
obtained from women with breast gross cystic disease and used
for production of mAbs. These mAbs are suitable for detection
of ZAG by immunoprecipitation and Western blot analyses,
andmay serve as useful reagents for clinical evaluation of ZAG
as a biochemical marker of tumors with specific patterns of
hormone responsiveness (5, 7). Our inability to produce crys-
tals of ZAG purified from cyst f luid prompted us to isolate
ZAG from serum using one of the anti-ZAG mAbs for
immunoaffinity chromatography. Additional chromatographic
steps resulted in fractionation of ZAG into different forms,
one of which yielded well ordered crystals.
ZAG purified from serum and cyst f luid consists of a single
chain, by contrast to the related class I MHC molecules, which
are heterodimers consisting of a membrane-bound heavy chain
associated with b2m, a soluble light chain. To investigate
whether ZAG is capable of binding the class I light chain, we
incubated purified ZAG with human b2m. No sign of a
ZAGyb2m heterodimer was observed by size exclusion chro-
matography. In addition, immunoprecipitation studies using
antibodies against either ZAG or b2m showed that the two
proteins do not coprecipitate from human serum. Therefore,
unlike most classical and nonclassical class I MHC proteins,
ZAG is not associated with the class I light chain, a charac-
teristic it shares with MICA, a divergent member of the class
I MHC family (34).
Class I MHCmolecules require bound peptide for structural
stability (20, 27, 28). Although ZAG is secreted from cells,
differing from conventional class I MHC molecules and most
MHC homologs which are cell surface proteins, soluble ver-
sions of H-2Kd (20) and HLA-G (35) have been shown to bind
peptides derived from endogenous proteins. We therefore
examined purified ZAG for the presence of bound peptide.
Peptides were not detected in acid eluates derived from ZAG,
by contrast to results obtained with the Kd eluate. To ascertain
if ZAG is stably folded in the absence of bound peptide and
b2m, we compared the thermal denaturation profile of ZAG
with denaturation profiles of class I molecules. The CD-
monitored melting curve of purified ZAG indicated that this
protein is significantly more stable than empty class I mole-
cules (20), and as stable as peptide-filled class I MHC het-
erodimers (20, 30). The structural stability in the absence of
peptide or b2m binding indicates that the function of ZAG has
diverged from the peptide presentation and T cell interaction
functions of class I MHC molecules and seems to rule out the
previous suggestion that ZAG functions as a soluble MHC
protein to regulate the immune system (8). Several lines of
evidence suggest that ZAG is a carrier of a small molecular
mass compound.When the protein was originally isolated from
serum, it was noted that ZAG was bound to a yellow pigment
that could be removed upon denaturation (1), and we have
obtained similar results with ZAG isolated from breast cyst
f luid (L.M.S. and C.L.-O., unpublished results). Moreover,
immunological studies showed that ZAG carries a proteinase-
resistant, heat-stable substance whose injection induces glo-
merulonephritis in experimental animals (36). Taken together,
these data suggest that ZAG carries a low molecular mass
FIG. 4. Thermal denaturation profile of serum ZAG. The CD
signal at 223 nm is plotted as molar ellipticity per mean residue after
smoothing. Similar profiles were obtained using ZAG isolated from
cyst f luid. Thermal denaturation studies were repeated after denatur-
ation and dialysis to remove any potential ZAG ligands without any
effect on the denaturation profile.
FIG. 3. HPLC analysis of acid eluates from Kd, ZAG, and a control
with no protein. All peaks in the ZAG eluate were subjected to
N-terminal sequencing and mass spectrometry analysis. No peptides
were detected.
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ligand of a different chemical nature than the peptides bound
by MHC molecules, but further studies will be needed to
identify the nature of the ZAG ligand(s).
Class I MHC molecules acquire peptide during assembly of
their heavy and light chains in the endoplasmic reticulum (9).
Because ZAG follows the same biosynthetic pathway as class
I molecules, it has an opportunity to bind peptides in the
endoplasmic reticulum, yet the biochemical data reported here
show that it does not. The neonatal Fc receptor (FcRn) is
another class I MHC homolog that does not bind endogenous
peptides (37). The FcRn crystal structure reveals that the
FcRn counterpart of the MHC peptide binding groove is
closed (38), resulting in an MHC-like structure that is stable in
the absence of bound peptide (37). Two amino acid changes
with respect to MHC molecules are primarily responsible for
closure of the FcRn cleft: Arg-164 occludes the FcRn coun-
terpart of pocket A that is used by class I molecules for the
peptide N terminus (reviewed in ref. 11), and Pro-162 within
the a2 domain helix appears to be responsible for a kink that
closes one side of the cleft. Interestingly, ZAG is one of only
a few MHC-like molecules that contains a proline at the
position of FcRn Pro-162 (Pro-167 in mature ZAG; classical
human and murine class I molecules contain mainly valine, a
helix-forming residue, at this position). In addition to ZAG
and FcRn, proline is found at the analogous position in all CD1
sequences (39). The recent crystal structure of a murine CD1
molecule shows a kink in the a2 domain helix at the position
of its proline, and some of the same sort of underlying
structural changes that were seen in the FcRn structure (40).
At least one form of human CD1 binds lipids instead of peptide
antigens (41, 42), and the murine CD1 structure shows a
substantially deeper and more hydrophobic binding groove
than conventional class I molecules (40). The available struc-
tural evidence, therefore, suggests that a proline at this posi-
tion within the a2 domain helix could be indicative of a
structural rearrangement with respect to classical class I MHC
molecules, which might be predictive of a function other than
peptide binding. X-ray structural analysis of ZAG ultimately
should allow its comparison with MHC and MHC-related
molecules, and increase understanding of the function of ZAG
under physiological and cancerous conditions.
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